Intriguingly, DLBCL patients also exhibit recurrent loss of KMT2D in combination with EZH2 GOF [20,37], yet the composite effects of these mutations on the epigenetic network and the cancer phenotype are not well understood. The gene discussed is EZH2; the disease is cancer.